The dependence of tumor growth on angiogenesis has been recognized, and there is an overexpression of vascular endothelial growth factor (VEGF) and its receptor in many malignant tumors, which provides an important theoretical basis for the development of antiangiogenic drugs and targeted therapies. The gene discussed is VEGFA; the disease is cancer.